Recombinant human alpha-Synuclein (A30P) protein

SNCA, NACP, PARK1, PARK4, PD1, α-synuclein Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor, Parkinson disease 4, autosomal dominant Lewy body

A-Synuclein (A30P), SNCA, NACP, PARK1, alpha-Synuclein, Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor, Alpha synuclein, Alpha-synuclein isoform NACP140, alphaSYN, MGC105443, MGC110988, MGC127560, MGC64356, Non A beta component of AD amyloid, Non A4 component of amyloid precursor, Non-A-beta component of alzheimers disease amyloid, precursor of PARK 1, PARK 4, PARK4, Parkinson disease familial 1, PD 1, PD1, Synuclein alpha, SNA2003-10 µg, SNA2003-20 µg, SNA2003-50 µg, SNA2003-100 µg, SNA2003-250 µg, SNA2003-500 µg, SNA2003-1 mg, SNA2003-10, SNA2003-20, SNA2003-50, SNA2003-100, SNA2003-250, SNA2003-500, SNA2003-1

Park JY, et al. Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinsons disease. (Glia. 2008) {https://pubmed.ncbi.nlm.nih.gov/18449945/}; ; Kim KS, et al. Proteolytic cleavage of extracellular α-synuclein by plasmin: implications for Parkinson disease. (J Biol Chem. 2012) {https://pubmed.ncbi.nlm.nih.gov/22619171/}; ; Konno M, et al. Suppression of dynamin GTPase decreases α-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy. (Mol Neurodegener. 2012) {https://pubmed.ncbi.nlm.nih.gov/22892036/}

MDVFMKGLSK AKEGVVAAAE KTKQGVAEAP GKTKEGVLYV GSKTKEGVVH GVATVAEKTK EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL GKNEEGAPQE GILEDMPVDP DNEAYEMPSE EGYQDYEPEA